Hoth Therapeutics announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor, or EGFR, inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer, or NSCLC, pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer. The phase 2a dose ranging study as well as a proposed follow-up phase 2b safety and efficacy dose extension study; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOTH:
- Biotech Alert: Searches spiking for these stocks today
- After Massive Rally, HOTH Tanks on Private Placement
- Hoth Therapeutics price target lowered to $33 from $45 at EF Hutton
- Hoth Therapeutics announces at-the-market $10M private placement
- Hoth Therapeutics Skyrockets after FDA Greenlight for Skin Therapy Trial